-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: October 2010
Getting to Market: The Challenges of Technology Transfer
An article about BIO’s recent Technology Transfer Symposium. Getting to Market: The Challenges of Technology Transfer Attendees at special symposium focus on issues of commercializing and licensing biotech discoveries Read the post on BIOtech NOW
New Blogger
Patently Biotech has a new writer. My name is Roy Zwahlen and I am the new Intellectual Property manager at BIO. I am an attorney and political science undergraduate and fascinated with intellectual property policy. I am excited about this opportunity to enter the IP blogosphere. My hope is to provide information about BIO’s IP activities including conferences and amicus briefs. I also hope to reintroduce our IP staff and spotlight our BIO company members. Read More >
New Salmon Can Address a Myriad Of Problems
By Elliot Entis, co-founder of AquaBounty Technologies (From The Hill, Friday, October 8, 2010) Natural fish stocks have been so depleted in the past few decades that more than half of the salmon we consume here in the United States comes to us from “fish farming,” 97 percent of which is imported. That’s because we consume highly-desirable fish like salmon at least twice as fast as it can reproduce in the wild. In 1993, AquaBounty, Read More >
First Person: An Advocate for Healthcare Innovations Becomes a Patient
Patients are always on our minds at BIO as we work to increase access to safe and effective therapies by advancing policies that support innovation. We all have friends and family members living with chronic conditions or fighting life-threatening diseases, such as cancer, Parkinson’s or ALS. Disease hit close to home recently when a member of the BIO family, Deputy General Counsel for Healthcare Sandi Dennis, was diagnosed with breast cancer. Fortunately, it was caught Read More >
State of the Industry – From BIO Investor Forum 2010
Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter
